Praxis Precision Medicines reported a net loss of $69.3 million for Q1 2025, with research and development expenses significantly increasing to $60.8 million. The company maintains a strong cash position of $472.0 million, extending its runway into 2028.

Praxis Precision Medicines reported a net loss of $58.679 million for Q4 2024, an increase from the $26.878 million loss in Q4 2023. Revenue from collaboration was $7.463 million. The company's cash and cash equivalents significantly increased to $469.5 million, providing a cash runway into 2028.

Praxis Precision Medicines reported a net loss of $51.9 million for Q3 2024, with research and development expenses increasing to $41.9 million. The company's cash, cash equivalents, and marketable securities totaled $411.2 million as of September 30, 2024, providing a runway into 2027. Key clinical programs, including ulixacaltamide, vormatrigine, and relutrigine, are advancing towards registrational readiness.

Praxis Precision Medicines reported a net loss of $32.7 million for the second quarter of 2024. The company's cash and investments totaled $433.8 million as of June 30, 2024, providing a cash runway into 2027.

Praxis Precision Medicines reported a net loss of $39.6 million for the first quarter of 2024. The company's cash and investments reached $451.2 million as of April 30, 2024, extending the operational runway into 2027.

Praxis Precision Medicines reported a net loss of $26.9 million for the fourth quarter of 2023. The company's cash and cash equivalents as of December 31, 2023, combined with proceeds from January 2024 offerings, are expected to fund operations into 2026.

Praxis Precision Medicines reported a net loss of $24.6 million for the third quarter of 2023, with cash and cash equivalents totaling $101.1 million as of September 30, 2023, expected to support operations into Q1 2025. The company progressed its clinical programs, including the initiation of the Essential3 Phase 3 program for ulixacaltamide and the completion of dosing for Part 1 of the EMBRAVE study for elsunersen.

Praxis Precision Medicines reported a net loss of $34.3 million for the second quarter of 2023. The company's cash and cash equivalents were $124.3 million as of June 30, 2023, expected to support runway into Q1 2025.

Praxis Precision Medicines reported a net loss of $37.5 million for the first quarter of 2023. As of March 31, 2023, the company's cash and investments totaled $85.8 million, expected to fund operations into the second quarter of 2024. Each of the four clinical-stage programs has made meaningful progress this year and the company anticipate additional value inflecting milestones throughout the pipeline in the coming months.

Praxis Precision Medicines reported a net loss of $41.2 million for Q4 2022, with cash and investments of $100.5 million as of December 31, 2022. The company anticipates topline results for the ulixacaltamide Essential1 study in Q1 2023 and data from its clinical-stage epilepsy programs throughout 2023.

Praxis Precision Medicines reported a net loss of $43.9 million for the third quarter of 2022, with $123.7 million in cash and investments as of September 30, 2022, expected to fund operations into the first quarter of 2024. The company is advancing its pipeline with upcoming milestones including topline results from the PRAX-944 Essential1 study and initiation of studies for epilepsy programs.

Praxis Precision Medicines reported a net loss of $60.2 million for the second quarter of 2022. As of June 30, 2022, the company's cash, cash equivalents, and marketable securities totaled $165.4 million, expected to fund operations into the first quarter of 2024.

Praxis Precision Medicines reported a net loss of $68.7 million for the first quarter of 2022. As of March 31, 2022, the company's cash, cash equivalents, and marketable securities totaled $222.5 million, expected to fund operations into the third quarter of 2023.

Praxis Precision Medicines reported a net loss of $58.6 million for the fourth quarter of 2021. As of December 31, 2021, Praxis had $275.9 million in cash, cash equivalents and marketable securities.

Praxis Precision Medicines reported a net loss of $44.7 million for the third quarter ended September 30, 2021. The company's cash, cash equivalents, and marketable securities are expected to fund operations into the second quarter of 2023.

Praxis Precision Medicines reported a net loss of $36.4 million for the second quarter of 2021. As of June 30, 2021, the company's cash and investments totaled $339.2 million, expected to fund operations into the second quarter of 2023. The company is advancing its clinical programs with multiple trials across CNS disorders.

Praxis Precision Medicines reported a net loss of $27.4 million for the first quarter of 2021. As of March 31, 2021, Praxis had $270.8 million in cash, cash equivalents and marketable securities.

Praxis Precision Medicines reported a net loss of $25.7 million for the fourth quarter of 2020. As of December 31, 2020, the company had $296.6 million in cash and cash equivalents. The company's cash and cash equivalents as of December 31, 2020 are expected to fund operations into the fourth quarter of 2022.